Lin Elizabeth Yeu 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 17, 2025
Insider Transaction Report
Form 4
Lin Elizabeth Yeu
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-13+3,350→ 8,700 total - Sale
Common Stock
2025-06-16$41.08/sh−1,006$41,326→ 7,694 total - Exercise/Conversion
Restricted Stock Units
2025-06-13−3,350→ 0 total→ Common Stock (3,350 underlying)
Holdings
- 15,866(indirect: By Spouse)
Common Stock
- 12,040(indirect: By 401(k))
Common Stock
Footnotes (4)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]Each RSU represents a contingent right to receive one share of the Company's common stock.
- [F4]RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.